The billionaire-backed Parker Institute for Cancer Immunotherapy is investing and partnering with a biotech their researchers believe has the potential to develop a new-model CAR-T that can be better guided down narrow pathways and equipped with a convenient on/off switch to help avoid any fatal accidents.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,